Barclays PLC Trims Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Barclays PLC lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.3% in the fourth quarter, HoldingsChannel reports. The firm owned 323,496 shares of the company’s stock after selling 104,099 shares during the quarter. Barclays PLC’s holdings in Teva Pharmaceutical Industries were worth $7,129,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in TEVA. Robeco Institutional Asset Management B.V. grew its holdings in shares of Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $4,966,000. Asset Management One Co. Ltd. increased its stake in Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after purchasing an additional 58,413 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $3,340,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in Teva Pharmaceutical Industries by 2,018.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock valued at $23,368,000 after buying an additional 1,045,305 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $14.71 on Friday. The firm has a market cap of $16.68 billion, a P/E ratio of -10.14, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a 50-day simple moving average of $15.26 and a 200-day simple moving average of $17.58.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TEVA. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, Bank of America reduced their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.